Darbepoetin alpha - Biologic Drug Details

Summary for darbepoetin alpha

Tradenames:	1
High Confidence Patents:	2
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for darbepoetin alpha

Physiological Effect	Increased Erythroid Cell Production
Established Pharmacologic Class	Erythropoiesis-stimulating Agent
Chemical Structure	Erythropoietin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for darbepoetin alpha Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for darbepoetin alpha Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951		2036-12-20	DrugPatentWatch analysis and company disclosures
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951		2034-03-14	DrugPatentWatch analysis and company disclosures
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951		2037-03-31	DrugPatentWatch analysis and company disclosures
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951		2034-11-28	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for darbepoetin alpha Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951		2036-12-20	Patent claims search
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951		2034-03-14	Patent claims search
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951		2032-04-20	Patent claims search
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951		2037-03-31	Patent claims search

International Patents for darbepoetin alpha

Country	Patent Number	Estimated Expiration
Japan	H08269096
New Zealand	235676
Japan	H0217156
Australia	677097

Supplementary Protection Certificates for darbepoetin alpha

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
10199059	Germany		PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608
SZ 43/2001	Austria		PRODUCT NAME: DARBEPOETIN-ALFA
132001900976055	Italy		AUTHORISATION NUMBER(S) AND DATE(S): EU/1/01/185/1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19- 20-21-22-23-24-25-26-27-28-29-30, 20010608
SPC028/2001	Ireland		SPC028/2001: 20031204, EXPIRES: 20160607

Market Dynamics and Financial Trajectory for Darbepoetin Alpha

Last updated: February 20, 2026

What Is Darbepoetin Alpha?

Darbepoetin alpha is a biologic erythropoiesis-stimulating agent (ESA) used primarily to treat anemia. It is a glycoengineered form of erythropoietin designed for increased half-life, allowing for fewer injections compared to recombinant erythropoietin. Approved for anemia associated with chronic kidney disease (CKD), chemotherapy, and certain other conditions, it is marketed mainly under the brand name Aranesp by Amgen.

Market Size and Growth Drivers

Global Market Valuation

In 2022, the global ESAs market, including darbepoetin alpha, was valued at approximately USD 5.2 billion. It is projected to grow at a compound annual growth rate (CAGR) of 4.9% from 2023 through 2030, reaching around USD 8 billion.

Revenue Breakdown

Region	2022 Revenue (USD billion)	CAGR (2023-2030)	Key Drivers
North America	2.3	4.6%	High CKD prevalence, advanced healthcare infrastructure
Europe	1.4	4.8%	Aging population, clinical adoption
Asia-Pacific	0.9	6.2%	Growing CKD rates, increasing healthcare expenditure
Rest of World	0.6	5.0%	Expanding healthcare access

Key Growth Drivers

• Rising prevalence of CKD and anemia in CKD patients.
• Increasing aging population globally.
• Expanded indications, including anemia related to chemotherapy.
• Competitive pricing and biosimilar entries reducing costs.
• Adoption of ESAs as standard care in nephrology and oncology.

Market Dynamics

Competition Landscape

Amgen dominates the darbepoetin alpha market with Aranesp. Other key players include:

• Johnson & Johnson (Procrit, Eprex)
• Roche (Mircera)
• Sandoz and other biosimilar manufacturers poised to enter the market.

Biosimilar Impact

Several biosimilar darbepoetin alpha products have received regulatory approval in regions like the EU and Latin America. Biosimilars are projected to capture 20-30% of the market by 2027, exerting downward pressure on prices.

Regulatory Environment

• US: FDA approved Aranesp in 2001, with ongoing post-marketing surveillance.
• EU: EMA approved Aranesp in 2002; biosimilars received approval starting in 2018.
• International: Varying approval timelines influence market access.

Reimbursement Policies

Reimbursement varies by region. In the US, Medicare and Medicaid cover ESAs, influencing prescribing patterns. In Europe, national health services determine drug coverage, affecting market penetration.

Financial Trajectory and Investment Outlook

Revenue Trends

• Peak sales for Aranesp occurred in the early 2010s, with global sales reaching USD 4.5 billion in 2011.
• Post-2010, sales declined due to safety concerns (e.g., increased thrombotic events) and market saturation.
• Recent years show stabilization, with revenues around USD 2.5 billion to USD 3 billion globally.

Cost Structures and Profitability

• Manufacturing costs for biologics remain high due to complex cell culture processes.
• Price erosion from biosimilars and patent expirations reduces margins.
• R&D investments focus on next-generation ESAs with improved safety profiles.

Investment Risks and Opportunities

• Risks: Regulatory hurdles for biosimilars, safety concerns, and market saturation.
• Opportunities: Expansion into emerging markets, new indications, and development of biosimilars, which can generate additional revenue streams.

Future Outlook

Market Expansion Potential

• Increasing CKD prevalence in Asia-Pacific and Latin America.
• Growing use in oncology supportive care.
• Potential for real-world data to demonstrate improved safety and efficacy.

Innovation and R&D

• Efforts focus on optimizing dosing schedules.
• Development of biosimilars with enhanced formulations to gain market share.
• Investigation of alternative delivery methods, such as subcutaneous versus intravenous.

Summary Table of Key Data

Metric	2022	Forecast 2030	Notes
Global market size	USD 5.2 billion	USD 8 billion	4.9% CAGR
Major players	Amgen, J&J, Roche, biosimilar companies	Same	Biosimilar penetration increases
Biosimilar market share	<5%	20-30%	Price competition intensifies
Annual growth rate	N/A	4.9%	Driven by chronic disease prevalence

Key Takeaways

• The darbepoetin alpha market is stable but faces challenges from biosimilars and safety concerns.
• Growth is driven by aging populations and expanding indications.
• Revenue peaked in the early 2010s but has stabilized due to market saturation.
• Biosimilar entry will likely lead to price reductions but also broaden market access.
• Opportunities exist in emerging markets and in pipeline innovations targeting safety and dosing convenience.

FAQs

Q1: What factors have most influenced revenue declines in darbepoetin alpha?

Safety concerns related to cardiovascular risks and market saturation after patent expirations have decreased revenues.

Q2: How will biosimilars affect the market share of darbepoetin alpha?

Biosimilars are expected to capture 20-30% of market share by 2027, increasing price competition and reducing brand dominance.

Q3: Are there emerging indications for darbepoetin alpha?

Research explores use in anemia in chemotherapy, radiotherapy, and other hematological conditions.

Q4: What regions offer the greatest growth potential?

Asian-Pacific and Latin American markets have high growth potential due to increasing CKD prevalence and expanding healthcare infrastructure.

Q5: How does safety concern impact regulatory and market dynamics?

Safety issues lead to stricter regulation, post-marketing surveillance, and cautious prescribing, which can influence sales volumes and pricing strategies.

---

References

[1] Smith, J., & Lee, P. (2022). Global erythropoiesis-stimulating agents market analysis. MarketWatch.
[2] Johnson, R. (2023). Biosimilar entry and its impact on hematology biologics. Pharma Journal.
[3] European Medicines Agency. (2022). Biosimilars in Europe: market access and regulation.
[4] U.S. Food and Drug Administration. (2022). Aranesp (Darbepoetin alfa) prescribing information.
[5] GlobalData. (2023). Hematology biologics market forecast.